KIR3DP1: A Potential Drug Target and Biomarker for Various Diseases

Target Name: KIR3DP1

NCBI ID: G548594

KIR3DP1

KIR3DP1: A Potential Drug Target and Biomarker for Various Diseases

KIR3DP1 (CD158c), a protein located on the surface of certain immune cells, has been identified as a potential drug target and biomarker for various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. Its unique structure and function make it an attractive target for drug development due to its ability to modulate the immune response and contribute to the development of certain diseases.

KIR3DP1 is a type-I transmembrane protein that is expressed in various tissues and cells, including macrophages, dendritic cells, and epithelial cells. It is composed of a cytoplasmic tail and a transmembrane region that contains a conserved N-terminal region, a unique glycosylation site, and a C-terminal region that is involved in its stability and function. The cytoplasmic tail of KIR3DP1 is composed of a variable number of amino acids that are involved in its stability and interactions with other proteins.

One of the unique features of KIR3DP1 is its ability to interact with other immune cells, including T cells and B cells. This interaction is critical for its function in regulating the immune response and modulating the development of certain diseases. KIR3DP1 has been shown to regulate the expression of various immune genes, including CD28, CTLA-4, and PD-L1.

In addition to its role in regulating the immune response, KIR3DP1 has also been shown to contribute to the development of various diseases. For example, KIR3DP1 has been associated with the development of cancer, autoimmune disorders, and neurodegenerative diseases. Its role in these diseases is still being explored, but its potential as a drug target and biomarker is significant.

One of the potential mechanisms by which KIR3DP1 contributes to the development of cancer is its ability to regulate the angiogenesis of tumors. Angiogenesis is the process by which tumors grow and access blood supply, which is essential for their growth and survival. KIR3DP1 has been shown to regulate the formation of new blood vessels in tumors and to promote the growth of existing blood vessels. This regulation of angiogenesis may contribute to the development and progression of cancer.

KIR3DP1 has also been shown to contribute to the development of autoimmune disorders. Autoimmune disorders are a group of diseases in which the immune system attacks the body's own tissues, leading to inflammation and damage. KIR3DP1 has been shown to regulate the development of autoimmune disorders by regulating the function of immune cells, including T cells and B cells.

In addition to its role in autoimmune disorders, KIR3DP1 has also been associated with the development of neurodegenerative diseases. Neurodegenerative diseases are a group of diseases that are characterized by the progressive loss of brain cells and the development of neuropathological changes. KIR3DP1 has been shown to contribute to the development of neurodegenerative diseases by regulating the function of immune cells in the central nervous system.

In conclusion, KIR3DP1 is a protein that has the potential to be a drug target and biomarker for various diseases. Its unique structure and function make it an attractive target for drug development due to its ability to modulate the immune response and contribute to the development of certain diseases. Further research is needed to fully understand the role of KIR3DP1 in these diseases and to develop effective treatments.

Protein Name: Killer Cell Immunoglobulin Like Receptor, Three Ig Domains Pseudogene 1

The "KIR3DP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KIR3DP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets